Bicara Therapeutics company information, Employees & Contact Information

Bicara Therapeutics Announces Ficerafusp Alfa Granted GlobeNewswire

Bicara Therapeutics to Participate in Upcoming Investor Conferences Yahoo Finance

Bicara Therapeutics Gets FDA Breakthrough for ficerafusp | BCAX Stock News Stock Titan

Bicara Therapeutics Inc. Announces Updated Interim Data from Phase 1/1b Trial of Ficerafusp Alfa in Head and Neck Cancer Ahead of ASCO Presentation Nasdaq

ASCO 2025 preview – Merus tops Bicara | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race Fierce Biotech

Bicara Therapeutics: Promising, But Only For The Patient (NASDAQ:BCAX) Seeking Alpha

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Bicara Responds to Rival Merus With Early Survival Data at ASCO25 BioSpace

Bicara Therapeutics Presents Promising Data for Ficerafusp Alfa at AACR Annual Meeting 2025 Nasdaq

Breakthrough Cancer Drug Shows 64% Response Rate in Head & Neck Cancer Trial | BCAX Stock News Stock Titan

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer Nasdaq

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference GlobeNewswire

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire

Bicara Therapeutics Announces First Patients Enrolled in GlobeNewswire

Bicara Therapeutics Reports Encouraging Phase 1/1b Data for Ficerafusp Alfa in Combination with Pembrolizumab for Squamous Cancer of the Anal Canal Nasdaq

Frontline Ficerafusp Alfa Plus Pembrolizumab Shows Promise in HPV-Negative HNSCC OncLive

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference GlobeNewswire

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering Yahoo Finance

Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing Business Wire

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? Yahoo Finance

ASCO 2025 – Bicara's ficerafusp claim turns to PD-L1 status | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Claire Mazumdar Fierce Pharma

ASCO25: Bicara stumbles on head-and-neck cancer readout FirstWord Pharma

Why Bicara Therapeutics Is Rising In Pre-market? Nasdaq

ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer Clinical Trials Arena

Bicara Therapeutics Announces Closing of $362 Million GlobeNewswire

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity Pharmaceutical Technology

Bicara Therapeutics Appoints Kate Haviland and Scott Robertson to Board citybiz

Bicara stock jumps after FDA grants breakthrough therapy status Investing.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) Seeking Alpha

'One of the lucky few': Bicara's CEO on operating in today's market, while hoping for a different one Fierce Biotech

ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset Fierce Biotech

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint The Business Journals

Bicara Thera earns FDA Breakthrough status for ficerafusp alfa The Pharma Letter

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO Reuters

Bicara chases Merus | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bicara presents promising early-stage data in head and neck cancers The Business Journals

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity (NASDAQ:BCAX) Seeking Alpha

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer Business Wire

TPG-backed Bicara Therapeutics raises $315 mln in US IPO Reuters

Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) Seeking Alpha

Bicara Therapeutics reports interim data from Phase I/Ib HNSCC treatment trial Clinical Trials Arena

This cancer drug developer held the Bay State's largest IPO of 2024 The Business Journals

Bicara stock falls after data for lead drug (BCAX:NASDAQ) Seeking Alpha

Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs Fierce Biotech

Biocon accused of committing IP theft to create cancer biotech Bicara Fierce Biotech

Bicara nets second nine-digit haul in nine months, raising $165M series C Fierce Biotech

Bicara Therapeutics: Clinical-Stage Biotechnology Company Raises Oversubscribed $165 Million Funding Round Pulse 2.0

BCAX Stock Price and Chart — NASDAQ:BCAX TradingView

With IPO, have the capital and resources for clinical studies: Bicara CEO The Economic Times

Two local biotechs go public, raising $540 million total The Boston Globe

Strong Wall Street Debut Shows Potential Of Indian Billionaire-Backed Bicara’s Cancer Drugs Forbes

Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy Business Wire

Bicara debuts with $40M from Biocon to bankroll bifunctional antibodies Fierce Biotech

Biocon Founder Kiran Mazumdar-Shaw Celebrates Niece's Bicara Therapeutics Nasdaq Debut ABP Live English

Biocon's Bicara Therapeutics Ceases to Be Associate Company Rediff MoneyWiz

Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public financialexpress.com